Dysfunction of immune system in the development of large granular lymphocyte leukemia

References

• Matutes E. Large granular lymphocytic leukemia. Current diagnostic and therapeutic approaches and novel treatment options. Expert Rev Hematol. 2017 Mar;10(3):251–258. doi: 10.1080/17474086.2017.1284585
   PubMed Web of Science ®Google Scholar
• Loughran TP. Large granular lymphocytic leukemia: an overview. Hospital Practice (1995). 1998 May 15;33(5):133–138. doi: 10.1080/21548331.1998.11443695
   PubMed Web of Science ®Google Scholar
• Sutton VR, Davis JE, Cancilla M, et al. Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation. J. Exp. Med. 2000 Nov 20;192(10):1403–1414. doi: 10.1084/jem.192.10.1403
   PubMed Web of Science ®Google Scholar
• Schrenk KG, Krokowski M, Feller AC, et al. Clonal T-LGL population mimicking leukemia in Felty’s syndrome--part of a continuous spectrum of T-LGL proliferations? Ann. Hematol. 2013 Jul;92(7):985–987. doi: 10.1007/s00277-012-1649-1
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi: 10.1182/blood-2016-01-643569
   PubMed Web of Science ®Google Scholar
• Bockorny B, Dasanu CA. Autoimmune manifestations in large granular lymphocyte leukemia. Clin Lymphoma Myeloma Leuk. 2012 Dec;12(6):400–405. doi: 10.1016/j.clml.2012.06.006
   PubMed Web of Science ®Google Scholar
• Lamy T, Loughran TP, Jr. Current concepts: large granular lymphocyte leukemia. Blood Rev. 1999 Dec;13(4):230–240. doi: 10.1054/blre.1999.0118
   PubMed Web of Science ®Google Scholar
• Sokol L, Loughran TP, Jr. Large granular lymphocyte leukemia. Oncologist. 2006 Mar;11(3):263–273. doi: 10.1634/theoncologist.11-3-263
   PubMed Web of Science ®Google Scholar
• Sokol L, Loughran TP, Jr. Large granular lymphocyte leukemia. Curr Hematol Malig Rep. 2007 Oct;2(4):278–282. doi: 10.1007/s11899-007-0038-7
   PubMedGoogle Scholar
• Zhang R, Shah MV, Loughran TP, Jr. The root of many evils: indolent large granular lymphocyte leukaemia and associated disorders. Hematol Oncol. 2010 Sep;28(3):105–117.
   PubMed Web of Science ®Google Scholar
• Lamy T, Moignet A, Loughran TP, Jr. LGL leukemia: from pathogenesis to treatment. Blood. 2017 Mar 2;129(9):1082–1094. doi: 10.1182/blood-2016-08-692590
   PubMed Web of Science ®Google Scholar
• Liu X, Loughran TP, Jr. The spectrum of large granular lymphocyte leukemia and Felty’s syndrome. Curr. Opin. Hematol. 2011 Jul;18(4):254–259. doi: 10.1097/MOH.0b013e32834760fb
   PubMed Web of Science ®Google Scholar
• Leblanc F, Zhang D, Liu X, et al. Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets. Future Oncology (London, England). 2012 Jul;8(7):787–801. doi: 10.2217/fon.12.75
   PubMed Web of Science ®Google Scholar
• Steinway SN, LeBlanc F, Loughran TP, Jr. The pathogenesis and treatment of large granular lymphocyte leukemia. Blood Rev. 2014 May;28(3):87–94. doi: 10.1016/j.blre.2014.02.001
   PubMed Web of Science ®Google Scholar
• Morice WG, Kurtin PJ, Tefferi A, et al. Distinct bone marrow findings in T-cell granular lymphocytic leukemia revealed by paraffin section immunoperoxidase stains for CD8, TIA-1, and granzyme B. Blood. 2002 Jan 1;99(1):268–274. doi: 10.1182/blood.V99.1.268
   PubMed Web of Science ®Google Scholar
• Berliner N, Horwitz M, Loughran TP, Jr. Congenital and acquired neutropenia. Hematol American Soc Hematol Education Program. 2004: 63–79.
   PubMedGoogle Scholar
• Mailloux AW, Zhang L, Moscinski L, et al. Fibrosis and subsequent cytopenias are associated with basic fibroblast growth factor-deficient pluripotent mesenchymal stromal cells in large granular lymphocyte leukemia. J Immunol. 2013 Oct 01;191(7):3578–3593. doi: 10.4049/jimmunol.1203424
   PubMed Web of Science ®Google Scholar
• Reda G, Fattizzo B, Cassin R, et al. Multifactorial neutropenia in a patient with acute promyelocytic leukemia and associated large granular lymphocyte expansion: a case report. Oncol Lett. 2017 Mar;13(3):1307–1310. doi: 10.3892/ol.2016.5549
   PubMed Web of Science ®Google Scholar
• Pontikoglou C, Kalpadakis C, Papadaki HA. Pathophysiologic mechanisms and management of neutropenia associated with large granular lymphocytic leukemia. Expert Rev Hematol. 2011 Jun;4(3):317–328. doi: 10.1586/ehm.11.26
   PubMed Web of Science ®Google Scholar
• Cooper DL, Henderson-Bakas M, Berliner N. Lymphoproliferative disorder of granular lymphocytes associated with severe neutropenia. Response to granulocyte colony-stimulating factor. Cancer. 1993 Sep 1;72(5):1607–1611. doi: 10.1002/1097-0142(19930901)72:5<1607::AID-CNCR2820720519>3.0.CO;2-N
   PubMed Web of Science ®Google Scholar
• Vickers M, Stross P, Millard P, et al. Response of T-beta CD8+ lymphocytosis-associated neutropenia to G-CSF. Br J Haematol. 1994 Jun;87(2):431–433. doi: 10.1111/j.1365-2141.1994.tb04940.x
   PubMed Web of Science ®Google Scholar
• Lamy T, LePrise PY, Amiot L, et al. Response to granulocyte-macrophage colony-stimulating factor (GM-CSF) but not to G-CSF in a case of agranulocytosis associated with large granular lymphocyte (LGL) leukemia. Blood. 1995 Jun 1;85(11):3352–3353.
   PubMed Web of Science ®Google Scholar
• Subbiah V, Viny AD, Rosenblatt S, et al. Outcomes of splenectomy in T-cell large granular lymphocyte leukemia with splenomegaly and cytopenia. Exp Hematol. 2008 Sep;36(9):1078–1083. doi: 10.1016/j.exphem.2008.04.005
   PubMed Web of Science ®Google Scholar
• Mohan SR, Clemente MJ, Afable M, et al. Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia. Haematologica. 2009 Oct;94(10):1407–1414. doi: 10.3324/haematol.2009.009191
   PubMed Web of Science ®Google Scholar
• Chen X, Bai F, Sokol L, et al. A critical role for DAP10 and DAP12 in CD8+ T cell-mediated tissue damage in large granular lymphocyte leukemia. Blood. 2009 Apr 02;113(14):3226–3234. doi: 10.1182/blood-2008-07-168245
   PubMed Web of Science ®Google Scholar
• Cornec D, Devauchelle-Pensec V, Jousse-Joulin S, et al. Long-term remission of T-cell large granular lymphocyte leukemia associated with rheumatoid arthritis after rituximab therapy. Blood. 2013 Aug 29;122(9):1583–1586. doi: 10.1182/blood-2013-03-491464
   PubMed Web of Science ®Google Scholar
• Loughran TP, Jr., Starkebaum G. Clinical features in large granular lymphocytic leukemia. Blood. 1987 Jun;69(6):1786, PubMed PMID: 3580580; eng.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Li CY, Witzig TE, et al. Chronic natural killer cell lymphocytosis: a descriptive clinical study. Blood. 1994 Oct 15;84(8):2721–2725.
   PubMed Web of Science ®Google Scholar
• Lamy T, Bauer FA, Liu JH, et al. Clinicopathological features of aggressive large granular lymphocyte leukaemia resemble Fas ligand transgenic mice. Br J Haematol. 2000 Mar;108(4):717–723. doi: 10.1046/j.1365-2141.2000.01934.x
   PubMed Web of Science ®Google Scholar
• Watters RJ, Liu X, Loughran TP, Jr. T-cell and natural killer-cell large granular lymphocyte leukemia neoplasias. Leuk Lymphoma. 2011 Dec;52(12):2217–2225. doi: 10.3109/10428194.2011.593276
   PubMed Web of Science ®Google Scholar
• Loughran TP, Jr., Hadlock KG, Yang Q, et al. Seroreactivity to an envelope protein of human T-cell leukemia/lymphoma virus in patients with CD3- (natural killer) lymphoproliferative disease of granular lymphocytes. Blood. 1997 Sep 01;90(5):1977–1981.
   PubMed Web of Science ®Google Scholar
• Fischer L, Hummel M, Burmeister T, et al. Skewed expression of natural-killer (NK)-associated antigens on lymphoproliferations of large granular lymphocytes (LGL). Hematol Oncol. 2006 Jun;24(2):78–85. doi: 10.1002/hon.777
   PubMed Web of Science ®Google Scholar
• Wei S, Gilvary DL, Corliss BC, et al. Direct tumor lysis by NK cells uses a Ras-independent mitogen-activated protein kinase signal pathway. J Immunol. 2000 Oct 01;165(7):3811–3819. doi: 10.4049/jimmunol.165.7.3811
   PubMed Web of Science ®Google Scholar
• Jiang K, Zhong B, Gilvary DL, et al. Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells. Nat Immunol. 2000 Nov;1(5):419–425. doi: 10.1038/80859
   PubMed Web of Science ®Google Scholar
• Epling-Burnette PK, Sokol L, Chen X, et al. Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling. Blood. 2008 Dec 01;112(12):4694–4698. doi: 10.1182/blood-2008-02-136382
   PubMed Web of Science ®Google Scholar
• Bassan R, Pronesti M, Buzzetti M, et al. Autoimmunity and B-cell dysfunction in chronic proliferative disorders of large granular lymphocytes/natural killer cells. Cancer. 1989 Jan 01;63(1):90–95. doi: 10.1002/1097-0142(19890101)63:1<90::AID-CNCR2820630115>3.0.CO;2-F
   PubMed Web of Science ®Google Scholar
• Pawarode A, Baer M. T/B and not T/B: high frequency of B-cell dyscrasias in T-LGL leukemia. Leuk. Lymphoma. 2008 May;49(5):845–846. doi: 10.1080/10428190802064966
   PubMed Web of Science ®Google Scholar
• Rose MG, Berliner N. T-cell large granular lymphocyte leukemia and related disorders. Oncologist. 2004;9(3):247–258. doi: 10.1634/theoncologist.9-3-247
   PubMed Web of Science ®Google Scholar
• Viny AD, Lichtin A, Pohlman B, et al. Chronic B-cell dyscrasias are an important clinical feature of T-LGL leukemia. Leuk Lymphoma. 2008 May;49(5):932–938. doi: 10.1080/10428190801932635
   PubMed Web of Science ®Google Scholar
• Kingreen D, Dalal BI, Heyman M, et al. Lymphocytosis of large granular lymphocytes in patients with Hodgkin’s disease. Am J Hematol. 1995 Dec;50(4):234–236. doi: 10.1002/ajh.2830500403
   PubMed Web of Science ®Google Scholar
• Lesesve JF, Feugier P, Lamy T, et al. Association of B-chronic lymphocytic leukaemia and T-large granular lymphocyte leukaemia. Clin Lab Haematol. 2000 Apr;22(2):121–122. doi: 10.1046/j.1365-2257.2000.00294.x
   PubMedGoogle Scholar
• Marolleau JP, Henni T, Gaulard P, et al. Hairy cell leukemia associated with large granular lymphocyte leukemia: immunologic and genomic study, effect of interferon treatment. Blood. 1988 Aug;72(2):655–660.
   PubMed Web of Science ®Google Scholar
• Papadaki T, Stamatopoulos K, Kosmas C, et al. Clonal T-large granular lymphocyte proliferations associated with clonal B cell lymphoproliferative disorders: report of eight cases. Leukemia. 2002 Oct;16(10):2167–2169. doi: 10.1038/sj.leu.2402643
   PubMed Web of Science ®Google Scholar
• Hu E, Weiss LM, Warnke R, et al. Non-Hodgkin’s lymphoma containing both B and T cell clones. Blood. 1987 Jul;70(1):287–292.
   PubMed Web of Science ®Google Scholar
• Ochs HD, Thrasher AJ. The Wiskott-Aldrich syndrome. J Allergy Clin Immunol. 2006 Apr;117(4):725–738 ; quiz 739. doi: 10.1016/j.jaci.2006.02.005
   PubMed Web of Science ®Google Scholar
• Loughran TP, Jr. Clonal diseases of large granular lymphocytes. Blood. 1993 Jul 01;82(1):1–14.
   PubMed Web of Science ®Google Scholar
• Liu JH, Wei S, Lamy T, et al. Blockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia. Blood. 2002 Aug 15;100(4):1449–1453.
   PubMed Web of Science ®Google Scholar
• Yang J, Epling-Burnette PK, Painter JS, et al. Antigen activation and impaired Fas-induced death-inducing signaling complex formation in T-large-granular lymphocyte leukemia. Blood. 2008 Feb 01;111(3):1610–1616. doi: 10.1182/blood-2007-06-093823
   PubMed Web of Science ®Google Scholar
• Shah MV, Zhang R, Loughran TP, Jr. Never say die: survival signaling in large granular lymphocyte leukemia. Clin Lymphoma Myeloma. 2009;9(Suppl 3):S244–S253. doi: 10.3816/CLM.2009.s.019
   PubMedGoogle Scholar
• Wlodarski MW, Schade AE, Maciejewski JP. T-large granular lymphocyte leukemia: current molecular concepts. Hematology. 2006 Aug;11(4):245–256. doi: 10.1080/10245330600774793
   PubMed Web of Science ®Google Scholar
• Gentile TC, Wener MH, Starkebaum G, et al. Humoral immune abnormalities in T-cell large granular lymphocyte leukemia. Leuk Lymphoma. 1996 Oct;23(3-4):365–370. doi: 10.3109/10428199609054840
   PubMed Web of Science ®Google Scholar
• Zhang R, Shah MV, Yang J, et al. Network model of survival signaling in large granular lymphocyte leukemia. Proc Natl Acad Sci U.S.A. 2008 Oct 21;105(42):16308–16313. doi: 10.1073/pnas.0806447105
   PubMed Web of Science ®Google Scholar
• Hayden MS, West AP, Ghosh S. NF-kappaB and the immune response. Oncogene. 2006 Oct 30;25(51):6758–6780. doi: 10.1038/sj.onc.1209943
   PubMed Web of Science ®Google Scholar
• Shah MV, Zhang R, Irby R, et al. Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes. Blood. 2008 Aug 1;112(3):770–781. doi: 10.1182/blood-2007-11-121871
   PubMed Web of Science ®Google Scholar
• Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol. 2006 Aug;6(8):595–601. doi: 10.1038/nri1901
   PubMed Web of Science ®Google Scholar
• Yu J, Ustach C, Kim HR. Platelet-derived growth factor signaling and human cancer. J Biochem Mol Biol. 2003 Jan 31;36(1):49–59.
   PubMedGoogle Scholar
• Tanaka M, Suda T, Haze K, et al. Fas ligand in human serum. Nat Med. 1996 Mar;2(3):317–322. doi: 10.1038/nm0396-317
   PubMed Web of Science ®Google Scholar
• Messinger Y, Gaynon P, Raetz E, et al. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer. 2010 Aug;55(2):254–259. doi: 10.1002/pbc.22456
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003 Jun 26;348(26):2609–2617. doi: 10.1056/NEJMoa030288
   PubMed Web of Science ®Google Scholar
• Morris JC, Janik JE, White JD, et al. Preclinical and phase I clinical trial of blockade of IL-15 using Mikbeta1 monoclonal antibody in T cell large granular lymphocyte leukemia. Proc Natl Acad Sci U.S.A. 2006 Jan 10;103(2):401–406. doi: 10.1073/pnas.0509575103
   PubMed Web of Science ®Google Scholar
• Waldmann TA, Conlon KC, Stewart DM, et al. Phase 1 trial of IL-15 trans presentation blockade using humanized Mikbeta1 mAb in patients with T-cell large granular lymphocytic leukemia. Blood. 2013 Jan 17;121(3):476–484. doi: 10.1182/blood-2012-08-450585
   PubMed Web of Science ®Google Scholar
• Prochorec-Sobieszek M, Rymkiewicz G, Makuch-Lasica H, et al. Characteristics of T-cell large granular lymphocyte proliferations associated with neutropenia and inflammatory arthropathy. Arthritis Res. Ther. 2008;10(3):R55, PubMed PMID: 18474096; PubMed Central PMCID: PMC2483444. doi: 10.1186/ar2424.
   PubMed Web of Science ®Google Scholar
• Go RS, Lust JA, Phyliky RL. Aplastic anemia and pure red cell aplasia associated with large granular lymphocyte leukemia. Semin Hematol. 2003 Jul;40(3):196–200. doi: 10.1016/S0037-1963(03)00140-9
   PubMed Web of Science ®Google Scholar
• Karadimitris A, Li K, Notaro R, et al. Association of clonal T-cell large granular lymphocyte disease and paroxysmal nocturnal haemoglobinuria (PNH): further evidence for a pathogenetic link between T cells, aplastic anaemia and PNH. Br J Haematol. 2001 Dec;115(4):1010–1014 doi: 10.1046/j.1365-2141.2001.03172.x
   PubMed Web of Science ®Google Scholar
• Go RS, Tefferi A, Li CY, et al. Lymphoproliferative disease of granular T lymphocytes presenting as aplastic anemia. Blood. 2000 Nov 15;96(10):3644–3646.
   PubMed Web of Science ®Google Scholar
• Akashi K, Shibuya T, Taniguchi S, et al. Multiple autoimmune haemopoietic disorders and insidious clonal proliferation of large granular lymphocytes. Br J Haematol. 1999 Dec;107(3):670–673. doi: 10.1046/j.1365-2141.1999.01734.x
   PubMed Web of Science ®Google Scholar
• Sandberg Y, Almeida J, Gonzalez M, et al. TCRgammadelta+ large granular lymphocyte leukemias reflect the spectrum of normal antigen-selected TCRgammadelta+ T-cells. Leukemia. 2006 Mar;20(3):505–513. doi: 10.1038/sj.leu.2404112
   PubMed Web of Science ®Google Scholar
• Rabbani GR, Phyliky RL, Tefferi A. A long-term study of patients with chronic natural killer cell lymphocytosis. Br J Haematol. 1999 Sep;106(4):960–966. doi: 10.1046/j.1365-2141.1999.01624.x
   PubMed Web of Science ®Google Scholar
• Risitano AM, Maciejewski JP, Muranski P, et al. Large granular lymphocyte (LGL)-like clonal expansions in paroxysmal nocturnal hemoglobinuria (PNH) patients. Leukemia. 2005 Feb;19(2):217–222. doi: 10.1038/sj.leu.2403617
   PubMed Web of Science ®Google Scholar
• Saunthararajah Y, Molldrem JL, Rivera M, et al. Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features. Br J Haematol. 2001 Jan;112(1):195–200. doi: 10.1046/j.1365-2141.2001.02561.x
   PubMed Web of Science ®Google Scholar
• Maciejewski JP, O'Keefe C, Gondek L, et al. Immune-mediated bone marrow failure syndromes of progenitor and stem cells: molecular analysis of cytotoxic T cell clones. Folia Histochem Cytobiol. 2007;45(1):5–14.
   PubMed Web of Science ®Google Scholar
• Gismondi A, Jacobelli J, Mainiero F, et al. Cutting edge: functional role for proline-rich tyrosine kinase 2 in NK cell-mediated natural cytotoxicity. J Immunol. 2000 Mar 01;164(5):2272–2276. doi: 10.4049/jimmunol.164.5.2272
   PubMed Web of Science ®Google Scholar
• Boztug K, Baumann U, Ballmaier M, et al. Large granular lymphocyte proliferation and revertant mosaicism: two rare events in a Wiskott-Aldrich syndrome patient. Haematologica. 2007 Mar;92(3):e43–e45. doi: 10.3324/haematol.11222
   PubMed Web of Science ®Google Scholar
• Lutskiy MI, Beardsley DS, Rosen FS, et al. Mosaicism of NK cells in a patient with Wiskott-Aldrich syndrome. Blood. 2005 Oct 15;106(8):2815–2817. doi: 10.1182/blood-2004-12-4724
   PubMed Web of Science ®Google Scholar
• Du W, Kumaki S, Uchiyama T, et al. A second-site mutation in the initiation codon of WAS (WASP) results in expansion of subsets of lymphocytes in an Wiskott-Aldrich syndrome patient. Hum Mutat. 2006 Apr;27(4):370–375. doi: 10.1002/humu.20308
   PubMed Web of Science ®Google Scholar
• Samanta A, Grant I, Nichol FE, et al. Large granular lymphocytosis associated with rheumatoid arthritis. Ann Rheum Dis. 1988 Oct;47(10):873–875. doi: 10.1136/ard.47.10.873
   PubMed Web of Science ®Google Scholar
• Prochorec-Sobieszek M, Chelstowska M, Rymkiewicz G, et al. Biclonal T-cell receptor gammadelta+ large granular lymphocyte leukemia associated with rheumatoid arthritis. Leuk Lymphoma. 2008 Apr;49(4):828–831. doi: 10.1080/10428190801895337
   PubMed Web of Science ®Google Scholar
• Starkebaum G. Leukemia of large granular lymphocytes and rheumatoid arthritis. Am J Med. 2000 Jun 15;108(9):744–745. doi: 10.1016/S0002-9343(00)00386-7
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Li CY, Lust JA, et al. Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance? Blood. 1994 Sep 1;84(5):1620–1627.
   PubMed Web of Science ®Google Scholar
• Rossoff LJ, Genovese J, Coleman M, et al. Primary pulmonary hypertension in a patient with CD8/T-cell large granulocyte leukemia: amelioration by cladribine therapy. Chest. 1997 Aug;112(2):551–553. doi: 10.1378/chest.112.2.551
   PubMed Web of Science ®Google Scholar
• Shvidel L, Duksin C, Tzimanis A, et al. Cytokine release by activated T-cells in large granular lymphocytic leukemia associated with autoimmune disorders. Hematol J. 2002;3(1):32–37. doi: 10.1038/sj.thj.6200149
   PubMedGoogle Scholar
• Ergas D, Tsimanis A, Shtalrid M, et al. T-gamma large granular lymphocyte leukemia associated with amegakaryocytic thrombocytopenic purpura, Sjogren’s syndrome, and polyglandular autoimmune syndrome type II, with subsequent development of pure red cell aplasia. Am J Hematol. 2002 Feb;69(2):132–134. doi: 10.1002/ajh.10024
   PubMed Web of Science ®Google Scholar
• Liu JH, Wei S, Lamy T, et al. Chronic neutropenia mediated by fas ligand. Blood. 2000 May 15;95(10):3219–3222.
   PubMed Web of Science ®Google Scholar
• Starkebaum G, Loughran TP, Jr. Gaur LK, et al. Immunogenetic similarities between patients with Felty’s syndrome and those with clonal expansions of large granular lymphocytes in rheumatoid arthritis. Arthritis Rheum. 1997 Apr;40(4):624–626. doi: 10.1002/art.1780400406
   PubMed Web of Science ®Google Scholar
• Melenhorst JJ, Brummendorf TH, Kirby M, et al. CD8+ t cells in large granular lymphocyte leukemia are not defective in activation- and replication-related apoptosis. Leuk. Res. 2001 Aug;25(8):699–708. doi: 10.1016/S0145-2126(01)00010-8
   PubMed Web of Science ®Google Scholar
• Loughran TP J, Hadlock KG, Perzova R, et al. Epitope mapping of HTLV envelope seroreactivity in LGL leukaemia. Br J Haematol. 1998 May;101(2):318–324. doi: 10.1046/j.1365-2141.1998.00691.x
   PubMed Web of Science ®Google Scholar
• Starkebaum G, Shasteen NM, Fleming-Jones RM, et al. Sera of patients with rheumatoid arthritis contain antibodies to recombinant human T-lymphotrophic virus type I/II envelope glycoprotein p21. Clin Immunol Immunopathol. 1996 May;79(2):182–188. doi: 10.1006/clin.1996.0065
   PubMedGoogle Scholar
• Sokol L, Agrawal D, Loughran TP, Jr. Characterization of HTLV envelope seroreactivity in large granular lymphocyte leukemia. Leuk Res. 2005 Apr;29(4):381–387. doi: 10.1016/j.leukres.2004.08.010
   PubMed Web of Science ®Google Scholar
• Lamy T, Loughran TP, Jr. Pathogenesis of autoimmune diseases in large granular lymphocyte leukemia. Hematology. 1998;3(1):17–29. doi: 10.1080/10245332.1998.11746376
   PubMedGoogle Scholar
• Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004 Jun 17;350(25):2572–2581. doi: 10.1056/NEJMoa032534
   PubMed Web of Science ®Google Scholar
• Weinreb N, Rabinowitz A, Dellaripa PF. Beneficial response to rituximab in refractory Felty syndrome. J Clin Rheumatol. 2006 Feb;12(1):48,. doi: 10.1097/01.rhu.0000200326.17729.76
   PubMed Web of Science ®Google Scholar
• Chandra PA, Margulis Y, Schiff C. Rituximab is useful in the treatment of Felty’s syndrome. Am J Ther. 2008 Jul–Aug;15(4):321–322. doi: 10.1097/MJT.0b013e318164bf32
   PubMed Web of Science ®Google Scholar
• Lamy T, Loughran TP, Jr. How I treat LGL leukemia. Blood. 2011 Mar 10;117(10):2764–2774. doi: 10.1182/blood-2010-07-296962
   PubMed Web of Science ®Google Scholar
• Oshimi K. Clinical features, pathogenesis, and treatment of large granular lymphocyte leukemias. Internal Med. 2017;56(14):1759–1769. doi: 10.2169/internalmedicine.56.8881
   PubMed Web of Science ®Google Scholar
• Koskela HL, Eldfors S, Ellonen P, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012 May 17;366(20):1905–1913. doi: 10.1056/NEJMoa1114885
   PubMed Web of Science ®Google Scholar
• Yue P, Turkson J. Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs. 2009 Jan;18(1):45–56. doi: 10.1517/13543780802565791
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012 Aug 9;367(6):495–507 doi: 10.1056/NEJMoa1109071
   PubMed Web of Science ®Google Scholar
• Traynor K. FDA approves tofacitinib for rheumatoid arthritis. Amer J Health-System Pharmacy. 2012 Dec 15;69(24):2120.
   Web of Science ®Google Scholar
• Liao A, Broeg K, Fox T, et al. Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia. Blood. 2011 Sep 8;118(10):2793–2800. doi: 10.1182/blood-2011-01-331447
   PubMed Web of Science ®Google Scholar
• Hodge DL, Yang J, Buschman MD, et al. Interleukin-15 enhances proteasomal degradation of bid in normal lymphocytes: implications for large granular lymphocyte leukemias. Cancer Res. 2009 May 1;69(9):3986–3994. doi: 10.1158/0008-5472.CAN-08-3735
   PubMed Web of Science ®Google Scholar
• Mishra A, Liu S, Sams GH, et al. Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. Cancer Cell. 2012 Nov 13;22(5):645–655. doi: 10.1016/j.ccr.2012.09.009
   PubMed Web of Science ®Google Scholar